Iterum Therapeutics plc
ITRMFNasdaqHealthcare · Pharmaceutical Preparations · L2 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $37,000 |
| Operating income | −$18.7M | −$47.5M | −$30.4M | −$24.5M | −$32.1M | −$102.0M |
| Net income | −$24.8M | −$38.4M | −$44.4M | −$91.6M | −$52.0M | −$103.1M |
| Total assets | $44.6M | $26.3M | $66.8M | $91.5M | $32.8M | $25.8M |
| Total liabilities | $48.7M | $32.7M | $38.8M | $41.3M | $83.4M | $52.0M |
| Equity | −$4.1M | −$6.4M | $28.0M | $50.2M | −$50.6M | −$26.2M |
| EPS (diluted) | $-1.26 | $-2.96 | $-3.63 | $-8.41 | $-32.49 | — |
| Shares out. | 16.4M | 12.7M | 182.8M | 176.5M | 14.9M | 14.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- 607.1%
- Return on assets
- −55.6%
- Return on capital (ROCE)
- −69.3%
- Liabilities / assets
- 109.2%
- Debt / equity
- —
- Book value / share
- $-0.25
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -37.38distress
- Accruals / assets
- 4.5%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.1M | 2.9 | -18.2% |
| Apr 30, 2026 | 1.4M | 2.8 | -20.4% |
| Apr 15, 2026 | 1.7M | 1.0 | -81.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard notice · Other material eventMar 31, 2026
- Bankruptcy or receivership · Debt acceleration / triggering event · Director / officer change · Regulation FD disclosureMar 27, 2026
- Other material eventMar 3, 2026
- Delisting / listing-standard noticeMar 2, 2026
- Shareholder vote · Other material eventFeb 18, 2026
- Delisting / listing-standard noticeDec 12, 2025
- Results of operationsNov 14, 2025
- Other material eventOct 16, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.